Esperion 与第六个ANDA申请人达成和解
Esperion已与Renata Limited达成和解，同意在2040年4月19日之前不上市NEXLETOL或NEXLIZET的仿制药，从而解决专利诉讼。
为什么重要. 此次结算影响Esperion对NEXLETOL和NEXLIZET的专利保护和市场独占权，进而影响其收入和竞争地位。
01
影响到谁
- 1Esperion
- 签署协议 →事实
02
证据
- GGlobeNewswire public company news公司披露2026-10-07 20:00
Esperion, a company wholly-owned by ARCHIMED, today announced that it has entered into a settlement agreement with Renata Limited (along with an affiliate).
- GGlobeNewswire public company news公司披露2026-10-07 20:00
This agreement resolves the patent litigation brought by Esperion against Renata in response to Renata’s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to…
- GGlobeNewswire public company news公司披露2026-10-07 20:00
The pending patent litigation against the remaining defendants (Aurobindo Pharma Limited (along with an affiliate); MSN Pharmaceuticals Inc. (along with an affiliate); and Sandoz Inc.) is ongoing, and there can be no assurance whether such ongoing patent litigation will allow a…